Endo International Plc (ENDP):企業の財務・戦略的SWOT分析

◆英語タイトル:Endo International Plc (ENDP) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1339
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Endo International Plc (ENDP) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Endo International Plc (Endo) is a specialty healthcare company that develops, manufactures and commercializes various branded pharmaceutical products, generic pharmaceuticals and other products through its operating companies. It sells generic products principally in the US in various categories including urology, pain management, central nervous system (CNS) disorders, immunosuppression, cancer, cardiovascular diseases and women’s health among others. The company offers branded pharmaceuticals for conditions related to urology, orthopedics, endocrinology and pain management. Endo also provides over-the-counter (OTC) products, which include dermatological products and anti-infectives. The company sells its products through independent wholesale distributors, to retailers, government agencies, doctors, clinics, independent retail and specialty pharmacies and independent specialty distributors. Endo is headquartered in Dublin, Ireland.

Endo International Plc Key Recent Developments

Feb 26,2020: Endo reports fourth-quarter and full-year 2019 financial results
Feb 19,2020: Endo names Blaise Coleman president and chief executive officer
Feb 19,2020: Endo appoints Mark G. Barberio to board of directors
Jan 10,2020: Endo settles ipioid investigation with State of Oklahoma for $8.75 million
Nov 05,2019: Endo International (ENDP) announces Paul V. Campanelli President and CEO to retire

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Endo International Plc – Key Facts
Endo International Plc – Key Employees
Endo International Plc – Key Employee Biographies
Endo International Plc – Major Products and Services
Endo International Plc – History
Endo International Plc – Company Statement
Endo International Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Endo International Plc – Business Description
Business Segment: International Pharmaceuticals
Overview
Performance
Business Segment: U.S. Branded – Specialty & Established Pharmaceuticals
Overview
Performance
Business Segment: U.S. Branded – Sterile Injectables
Overview
Performance
Business Segment: U.S. Generic Pharmaceuticals
Overview
Performance
Endo International Plc – Corporate Strategy
Endo International Plc – SWOT Analysis
SWOT Analysis – Overview
Endo International Plc – Strengths
Endo International Plc – Weaknesses
Endo International Plc – Opportunities
Endo International Plc – Threats
Endo International Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Endo International Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 26, 2020: Endo reports fourth-quarter and full-year 2019 financial results
Feb 19, 2020: Endo names Blaise Coleman president and chief executive officer
Feb 19, 2020: Endo appoints Mark G. Barberio to board of directors
Jan 10, 2020: Endo settles ipioid investigation with State of Oklahoma for $8.75 million
Nov 04, 2019: Endo implements CEO succession plan
Nov 04, 2019: Endo reports third-quarter 2019 financial results
Sep 05, 2019: Endo announces execution of final settlement agreement and release resolving “Track 1″ opioid cases
Aug 20, 2019: Endo announces settlement in principle to resolve “Track 1″ opioid cases
Aug 05, 2019: Endo Reports second-quarter 2019 financial results
Aug 01, 2019: Endo appoints Domenico Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Endo International Plc, Key Facts
Endo International Plc, Key Employees
Endo International Plc, Key Employee Biographies
Endo International Plc, Major Products and Services
Endo International Plc, History
Endo International Plc, Other Locations
Endo International Plc, Subsidiaries
Endo International Plc, Key Competitors
Endo International Plc, Ratios based on current share price
Endo International Plc, Annual Ratios
Endo International Plc, Annual Ratios (Cont...1)
Endo International Plc, Annual Ratios (Cont...2)
Endo International Plc, Interim Ratios
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Endo International Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Endo International Plc, Performance Chart (2015 - 2019)
Endo International Plc, Ratio Charts
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Endo International Plc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Endo International Plc (ENDP):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Malaysia Airlines Berhad:戦略・SWOT・企業財務分析
    Malaysia Airlines Berhad - Strategy, SWOT and Corporate Finance Report Summary Malaysia Airlines Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • YTL Power International Bhd (YTLPOWR):企業の財務・戦略的SWOT分析
    YTL Power International Bhd (YTLPOWR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Puracap Pharmaceutical LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Puracap Pharmaceutical LLC (PuraCap) is a drug development company that offers prescription generics and OTC products. The company provides over the counter soft gels and oral solid dosage healthcare products for upper respiratory, pain relief, cough and cold, sleep aid, gastrointestinal, an …
  • Evergreen Fibreboard Berhad:企業の戦略・SWOT・財務情報
    Evergreen Fibreboard Berhad - Strategy, SWOT and Corporate Finance Report Summary Evergreen Fibreboard Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Centrex Metals Ltd:企業の戦略・SWOT・財務分析
    Centrex Metals Ltd - Strategy, SWOT and Corporate Finance Report Summary Centrex Metals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Neuralstem Inc (CUR):企業の財務・戦略的SWOT分析
    Summary Neuralstem Inc (Neuralstem) is a biopharmaceutical company that develops novel treatments for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer’s disease, traumatic brain injury, peri …
  • NovoCure Ltd (NVCR)-医療機器分野:企業M&A・提携分析
    Summary NovoCure Ltd (NovoCure) is an drug company that concentrates on the development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in various types of cancer indications such as ovarian cancer, malignant melanoma, hepatocellul …
  • BioMarin Pharmaceutical Inc (BMRN):製薬・医療:M&Aディール及び事業提携情報
    Summary BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions, such as Kyndrisa (drisapersen), Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasi …
  • Mercuria Energy Group Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Mercuria Energy Group Ltd (Mercuria Energy) is an independent energy and commodity company that carries out sourcing, supplying and trading of crude oil and refined petroleum products through its subsidiaries. Its portfolio includes petrochemicals, biofuels, environmental products, natural g …
  • Greenbelt Resources Corp (GRCO):電力:M&Aディール及び事業提携情報
    Summary Greenbelt Resources Corp (GRC) is an alternative energy company that offers sustainable energy production systems delivering modular solutions that enable localized processing of locally generated waste into locally consumed products. The company designs, develops and implements technology t …
  • Sime Darby Bhd (SIME)
    Sime Darby Bhd (SIME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Gedeon Richter Plc:企業の戦略・SWOT・財務情報
    Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report Summary Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Four Seasons Hotels and Resorts:企業の戦略的SWOT分析
    Four Seasons Hotels and Resorts - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Neovacs SA (ALNEV):製薬・医療:M&Aディール及び事業提携情報
    Summary Neovacs SA (Neovacs) is a biotechnology company that develops various therapeutic vaccines for the treatment of autoimmune disorders, inflammatory diseases and cancers. The company offers TNF- kinoid and IFNalpha- kinoid products used for the treatment of rheumatoid arthritis, Crohn’s diseas …
  • Arden Partners Plc (ARDN):企業の財務・戦略的SWOT分析
    Summary Arden Partners Plc (Arden) is a multi-service stockbroker that provides a range of financial services to corporate and institutional clients. The company offers research, distribution, execution and corporate finance services. Its distribution services include providing unique trading though …
  • Banco Bradesco SA:企業の戦略・SWOT・財務情報
    Banco Bradesco SA - Strategy, SWOT and Corporate Finance Report Summary Banco Bradesco SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Isagen SA ESP:企業の戦略的SWOT分析
    Isagen SA ESP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Clean TeQ Holdings Ltd (CLQ):企業の財務・戦略的SWOT分析
    Summary Clean TeQ Holdings Ltd (Clean TeQ) is a clean technology company that offers air pollution control solutions using biotechnology-based processes. The company provides water treatment products such as advanced separations, advanced oxidation, encapsulated bacteria, continuous ionic filtration …
  • Legacy Reserves LP (LGCY):石油・ガス:M&Aディール及び事業提携情報
    Summary Legacy Reserves LP (Legacy Reserves) is an oil and gas exploration and production company that acquires and develops oil and natural gas properties in the Permian Basin, Mid-Continent and Rocky Mountain regions of the US. The company provides Permian Basin which is an oil and natural gas pro …
  • China Grand Pharmaceutical and Healthcare Holdings Ltd (512)-医療機器分野:企業M&A・提携分析
    Summary China Grand Pharmaceutical and Healthcare Holdings Ltd (China Grand) is an investment holding company that develops, manufacture and distributes pharmaceutical preparations, medical devices and pharmaceutical intermediates, specialized raw materials, and healthcare products. The company’s pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆